Gene therapy for brain tumors

Bansal, Kanti; Engelhard, Herbert H.

doi:10.1007/s11912-000-0067-z

Cited by 31 publications

(18 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the effectiveness of chemotherapy in combination with agents possessing differing and complementary mechanisms of action, such as angiogenesis inhibitors (for example, statins), resistance modifiers, apoptosis and immune stimulators (for example, p53 and herpes simplex virus thymidine kinase), and other agents that intervene in critical pathways of tumorigenesis and tumor growth will also need to be explored. 2,9,11,36,60,73,90,91,99,110,127 …”

Section: New Compounds For Local Deliverymentioning

confidence: 99%

Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies

Frazier¹,

Lee²,

Thomale

et al. 2009

PED

127

107

View full text Add to dashboard Cite

Diffuse intrinsic pontine gliomas constitute ~ 60–75% of tumors found within the pediatric brainstem. These malignant lesions present with rapidly progressive symptoms such as cranial nerve, long tract, or cerebellar dysfunctions. Magnetic resonance imaging is usually sufficient to establish the diagnosis and obviates the need for surgical biopsy in most cases. The prognosis of the disease is dismal, and the median survival is < 12 months. Resection is not a viable option. Standard therapy involves radiotherapy, which produces transient neurological improvement with a progression-free survival benefit, but provides no improvement in overall survival. Clinical trials have been conducted to assess the efficacy of chemotherapeutic and biological agents in the treatment of diffuse pontine gliomas. In this review, the authors discuss recent studies in which systemic therapy was administered prior to, concomitantly with, or after radiotherapy. For future perspective, the discussion includes a rationale for stereotactic biopsies as well as possible therapeutic options of local chemotherapy in these lesions.

show abstract

Section: New Compounds For Local Deliverymentioning

confidence: 99%

Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies

Frazier¹,

Lee²,

Thomale

et al. 2009

PED

127

107

View full text Add to dashboard Cite

show abstract

“…Current cancer treatment is rapidly evolving in parallel with an understanding of tumour biology (Weiss, 2000;Karpati and Nalbantoglu, 2003). Genetic abnormalities and differential gene expression between normal and cancer cells can provide novel targets for anticancer therapy (Lang et al, 1999;Bansal and Engelhard, 2000;Grill et al, 2001).…”

mentioning

confidence: 99%

Fatty acid synthase: a novel target for antiglioma therapy

et al. 2006

View full text Add to dashboard Cite

High levels of fatty acid synthase (FAS) expression have been observed in several cancers, including breast, prostate, colon and lung carcinoma, compared with their respective normal tissue. We present data that show high levels of FAS protein in human and rat glioma cell lines and human glioma tissue samples, as compared to normal rat astrocytes and normal human brain. Incubating glioma cells with the FAS inhibitor cerulenin decreased endogenous fatty acid synthesis by approximately 50%. Cell cycle analysis demonstrated a time-and dose-dependent increase in S-phase cell arrest following cerulenin treatment for 24 h. Further, treatment with cerulenin resulted in time-and dose-dependent decreases in glioma cell viability, as well as reduced clonogenic survival. Increased apoptotic cell death and PARP cleavage were observed in U251 and SNB-19 cells treated with cerulenin, which was independent of the death receptor pathway. Overexpressing Bcl-2 inhibited cerulenin-mediated cell death. In contrast, primary rat astrocytes appeared unaffected. Finally, RNAi-mediated knockdown of FAS leading to reduced FAS enzymatic activity was associated with decreased glioma cell viability. These findings suggest that FAS might be a novel target for antiglioma therapy.

show abstract

“…The resistance of brain tissue is a major factor which reduces delivery to brain beyond the catheter tip [6]. Such resistance can also unintentionally direct flow along the catheter tract, although this problem has been minimized by modifications in catheter design [7]. If a substance is being infused into a tumor cavity, gliosis at the cavity wall creates an additional barrier to the brain interface.…”

Section: Anatomic and Physiologic Considerationsmentioning

confidence: 99%

“…The transfer of genetic material into a patient's cell for therapeutic processes is the general definition for ''gene therapy [7].'' A broader definition includes transfer of genetic material to boost the immune system, enzyme prodrug therapy, oncoloytic therapy, transfer of tumor suppressor or anti-angiogenesis genes, or transfer of antisense oligonucleotides [7]. There are challenges with gene therapy which are inherent in the mode of drug delivery, and transduction efficiency.…”

Section: Gene Therapy Interstitial Wafers and Chemotherapymentioning

confidence: 99%

Current status of intratumoral therapy for glioblastoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

With emerging drug delivery technologies becoming accessible, more options are expected to become available to patients with glioblastoma (GBM) in the near future. It is important for clinicians to be familiar with the underlying mechanisms and limitations of intratumoral drug delivery, and direction of recent research efforts. Tumor-adjacent brain is an extremely complex living matrix that creates challenges with normal tissue intertwining with tumor cells. For convection-enhanced delivery (CED), the role of tissue anisotropy for better predicting the biodistribution of the infusate has recently been studied. Computational predictive methods are now available to better plan CED therapy. Catheter design and placement—in addition to the agent being used—are critical components of any protocol. This paper overviews intratumoral therapies for GBM, highlighting key anatomic and physiologic perspectives, selected agents (especially immunotoxins), and some new developments such as the description of the glymphatic system.

show abstract

Gene therapy for brain tumors

Cited by 31 publications

References 59 publications

Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies

Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies

Fatty acid synthase: a novel target for antiglioma therapy

Current status of intratumoral therapy for glioblastoma

Contact Info

Product

Resources

About